Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with ...

The list including Bristol-Myers Squibb’s cancer immunotherapy Opdivo (nivolumab), Eli Lilly’s Cyramza (ramucirumab), Eisai’s Lenvima (lenvatinib), Bayer’s Stivarga (regorafenib) ...

but prognosis for patients continues to be poor and there’s a big unmet need for drugs that can be used in the second-line setting alongside newer TKIs such as Bayer’s Stivarga (regorafenib ...

- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY ® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are ...

To sign up for Becker's GI & Endoscopy E-Newsletter or any of our other E-Newsletters, click here. If you are experiencing difficulty receiving our newsletters, you may need to whitelist our new ...

was 5.6 months for those who received the combination versus 2 months for those who received investigator’s choice standard trifluridine/tipiracil or regorafenib (Stivarga; Bayer). The Bruton tyrosine ...

The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.

Regorafenib (BAY 73-4506, Stivarga) is an anti-neoplastic agent. Regorafenib is formulated as film coated tablets and tablets for oral route of administration. It is indicated for the treatment of ...

The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) ...